Ann: Investor presentation, 15 May 2024, page-11

Being the dummy I am, I asked my friendly AI what the "undisclosed Applications " mentioned in the presentation may be.....some food for thort...

"The query about the "undisclosed applications" in Neuren Pharmaceuticals' commercial and late-stage pipeline for NNZ-2591, as mentioned in their investor presentation dated 15 May 2024, refers to potential therapeutic uses of NNZ-2591 that have not been publicly detailed by the company. While the specific applications remain undisclosed in the provided search results, we can infer possible areas based on the drug's existing clinical trials and the scientific properties of NNZ-2591.NNZ-2591 is currently in Phase 2 development for several neurodevelopmental disorders, including Phelan-McDermid syndrome, Angelman syndrome, Pitt Hopkins syndrome, and Prader-Willi syndrome. These disorders share common features such as developmental delays, intellectual disabilities, and sometimes, autistic behaviors. Given this, the undisclosed applications might involve other similar neurodevelopmental or neurological disorders where the drug's mechanism of action could be beneficial.The drug targets the SHANK3 gene, which plays a crucial role in synaptic development and function. This suggests potential applications in other conditions involving synaptic dysfunctions. For instance, other genetic syndromes involving mutations in genes related to synaptic function could be potential targets.Additionally, Neuren Pharmaceuticals holds a patent for the use of NNZ-2591 in treating Autism Spectrum Disorder (ASD), which expires in 2034. Although ASD does not receive orphan drug designation, the broad spectrum of autism disorders and the significant variation in symptoms present a substantial area for clinical application that might be explored under the undisclosed applications.Given the drug's impact on synaptic function, there could also be potential applications in neurodegenerative diseases such as Alzheimer's disease or other dementias, as these conditions also involve synaptic impairments.In summary, while the specific "undisclosed applications" for NNZ-2591 are not detailed in the available documents, the drug's ongoing trials and its mechanism of action suggest that it could potentially be applied to a range of neurodevelopmental and neurodegenerative disorders beyond those currently listed in its clinical development pipeline."